^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MLL translocation

i
Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
4ms
MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer. (PubMed, Clin Epigenetics)
MC180380, an inhibitor of cyclin-dependent kinase 9 (CDK9), is an efficacious anti-cancer agent worth advancing further toward clinical use.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
|
MLL translocation
|
decitabine
6ms
Genomic Analyses Unveil the Pathogenesis and Inform on Therapeutic Targeting in KMT2A-PTD AML (ASH 2023)
Given the results obtained with menin inhibitors in KMT2A-rearranged and NPM1-mutated AML, our findings open an opportunity for exploiting a therapeutic vulnerability in all HOX-AML including KMT2A-PTD AML or AML with high MEN1 expression. Since HOX-AML highly express genes according to the HOX differentiation profile, stage-specific surface proteins coded by these genes would be promising targets.
Genomic analysis
|
FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD276 (CD276 Molecule) • SRSF2 (Serine and arginine rich splicing factor 2) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • PML (Promyelocytic Leukemia) • CD34 (CD34 molecule) • STAG2 (Stromal Antigen 2) • CD14 (CD14 Molecule) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • MEN1 (Menin 1) • CD1D (CD1d Molecule) • CD86 (CD86 Molecule) • HOXB2 (Homeobox B2) • NKX2-3 (NK2 Homeobox 3)
|
NPM1 mutation • TET2 mutation • KMT2A rearrangement • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • STAG2 mutation • MLL mutation • MLL translocation • KMT2A expression • KMT2A-PTD • CD1D expression
7ms
Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b In Vivo (ASH 2023)
In this study, we present the in vivo effectiveness of DS-1594b in combination with venetoclax in a PDX model of NPM1-mutated AML. Moreover, the combination treatment exhibits differentiation-inducing effects, which contribute to its therapeutic effectiveness, and was safe. Overall, our findings strongly indicate that the combination of DS-1594b and venetoclax exhibits promising anti-leukemic activity in vivo and holds potential as a therapeutic strategy for AML patients with mtNPM1 mutations.
Preclinical • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • CD33 (CD33 Molecule) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3)
|
NPM1 mutation • CD38 expression • MLL rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
Venclexta (venetoclax) • DS-1594
7ms
CRISPR-ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia. (PubMed, Nat Struct Mol Biol)
As H3K79me2 has a putative oncogenic function in leukemia cells driven by MLL translocations, using CRISPR-ChIP we reveal a functional partitioning of H3K79 methylation into two distinct regulatory units: an oncogenic DOT1L complex directed by the MLL fusion protein in a Menin-dependent manner and a separate endogenous DOT1L complex, where catalytic activity is directed by MLLT10. Overall, CRISPR-ChIP provides a powerful tool for the unbiased interrogation of the mechanisms underpinning chromatin regulation.
Journal
|
DOT1L (DOT1 Like Histone Lysine Methyltransferase) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
|
MLL translocation • MLL fusion
10ms
CircR-looping the leukemic translocations: The cause of MLL translocations explained. (PubMed, Mol Cell)
identify circular RNAs (circRNAs) derived from mixed lineage leukemia (MLL) breakpoint cluster regions, demonstrating a causal role of circRNAs in MLL translocations. CircRNAs:DNA hybrids (circR-loops) trigger RNA polymerase pausing, driving oncogenic gene fusions via endogenous RNA-directed DNA damage.
Journal
|
BCR (BCR Activator Of RhoGEF And GTPase)
|
MLL translocation
almost1year
Activated Src kinases downstream of BCR-ABL and Flt3 induces proteasomal degradation of SHIP1 by phosphorylation of tyrosine 1021. (PubMed, Biochim Biophys Acta Mol Cell Res)
Inhibition of BCR-ABL (Imatinib), Flt3 (Quizartinib) or Src-Kinase-Family (Saracatinib) leads to significant reconstitution of SHIP1 protein expression. These results further support a functional role of SHIP1 as tumor suppressor protein and could be the basis for the establishment of a targeted therapy form.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KMT2A (Lysine Methyltransferase 2A) • INPP5D (Inositol Polyphosphate-5-Phosphatase D)
|
MLL translocation
|
imatinib • Vanflyta (quizartinib) • saracatinib (AZD0530)
1year
SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY (EHA 2023)
A steroid pre-phase (Prednisolone 100mg daily for 7 days) was followed by a disease debulking phase of cyclophosphamide 150mg/m 2 BD day 1-3, vincristine 2mg day 1 & 11 and dexamethasone 10mg/m 2 day 1-4 and 11-14...All received intrathecal prophylaxis with methotrexate, cytarabine and hydrocortisone prior to blinatumomab treatment blocks and day 1 and 8 of each B-cycle, total of 8 doses... Blinatumomab with chemotherapy was well tolerated with a high rate of remission and deep MRD responses in the majority of patients. Responses appeared durable with this lower intensity treatment approach despite a low rate of allogeneic stem cell transplantation and the exclusion of anthracyclines and asparaginase from treatment. Despite failing to meet proof-of-concept criteria the EFS and OS were encouragingfor older ALL patients and demonstrates the feasibility of combining low-intensity chemotherapy with blinatumomab in older adults with BCP-ALL.
Clinical
|
MLL translocation
|
cytarabine • cyclophosphamide • Blincyto (blinatumomab) • vincristine • dexamethasone
1year
A COMPLEX INTERPLAY OF INTRA- AND EXTRACELLULAR FACTORS REGULATES THE OUTCOME OF FETAL- AND ADULT-DERIVED MLL-REARRANGED LEUKEMIA (EHA 2023)
Our study provides a comprehensive resource of ontogeny- and malignancy-driven changes in the intra- and extracellular proteome of haematopoietic progenitor cells, which in combination with the results from our functional assays sheds new light on age-specific targetable pathways in MLLr leukaemia. Acute leukemia, Proteomics, MLL
Clinical
|
KMT2A (Lysine Methyltransferase 2A) • IGF2 (Insulin-like growth factor 2)
|
MLL rearrangement • MLL rearrangement • MLL translocation
over1year
DNA fragility at the KMT2A/MLL locus: insights from old and new technologies. (PubMed, Open Biol)
The Mixed-Lineage Leukaemia (MLL/KMT2A) gene is frequently rearranged in childhood and adult acute leukaemia (AL) and in secondary leukaemias occurring after therapy with DNA topoisomerase targeting anti-cancer agents such as etoposide (t-AL)...However, the t-AL hotspot and the centre of the observed preferential DNA cleavage are offset by over 250 nucleotides, suggesting additional factors contribute to the distribution of t-AL break sites. We review these recent genomic datasets along with older experimental results, analysis of TOP2 DNA cleavage site preferences and DNA secondary structure features that may lead to break site selection in t-AL MLL/KMT2A translocations.
Review • Journal
|
BCR (BCR Activator Of RhoGEF And GTPase) • KMT2A (Lysine Methyltransferase 2A)
|
MLL translocation
|
etoposide IV
over1year
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
TP53 mutation • NPM1 mutation • MLL rearrangement • MLL mutation • MLL translocation
over1year
Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation. (PubMed, Cancers (Basel))
To interrogate these mechanisms at higher resolution, advances in single-cell techniques have begun to highlight the heterogeneity of epigenomic landscapes and how these impact on gene expression within different AML populations in individual cells. Combined, these technologies provide a new lens through which to study the role of epigenetic modifications in normal hematopoiesis and how the underlying mechanisms can be hijacked in the context of malignancies such as AML.
Review • Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL rearrangement • MLL rearrangement • MLL translocation
over1year
IGF2BP3 Expression Correlates with Poor Survival in Primary and Relapsed Pediatric B-ALL (B-cell Acute Lymphoblastic Leukemia) in an Indian Cohort (ASH 2022)
This is in line with our previous work which shows that IGF2BP3 overexpression leads to progenitor expansion in the mouse marrow and is essential for development of MLL-AF4 induced leukemogenesis. Our work also provides strong rationale for targeting this machinery for therapy in B-ALL.
Clinical
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)
|
MLL translocation • IGF2BP1 overexpression • FTO expression
over1year
Optimized Method for Cell Surface Protein Identification on Primary B-Cell Precursor Acute Lymphoblastic Leukemia Cells (ASH 2022)
Conclusion s : We have optimized the method of cell surface protein identification on primary BCP-ALL samples (Fig.1). It allowed us to overcome the technical issues of proteomics analysis of samples from the patients and to identify a subset of surface proteins, which can be promising targets for immunotherapy.
IO biomarker
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • CD70 (CD70 Molecule) • CD79A (CD79a Molecule)
|
MLL rearrangement • MLL rearrangement • MLL translocation
over1year
The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia. (PubMed, Leukemia)
Therapeutically, YEATS containing MLL-ENL leukemic cells display increased sensitivity to the YEATS inhibitor SGC-iMLLT compared to control AML cells. Our results demonstrate that the YEATS domain is important for MLL-ENL fusion protein-mediated leukemogenesis and exposes an "Achilles heel" that may be therapeutically targeted for treating t(11;19) patients.
Journal
|
KMT2A (Lysine Methyltransferase 2A) • MEIS1 (Meis Homeobox 1) • MLLT1 (MLLT1 Super Elongation Complex Subunit)
|
MLL translocation • MLL fusion
over1year
Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells (ASH 2022)
As anticipated, pinometostat-resistant cells displayed a slight cross-resistance to most chemotherapeutic agents currently used in ALL treatments but became remarkably more sensitive toward the BCL-2 inhibitor venetoclax. Also, our model demonstrates that under prolonged pressure of DOT1L inhibition, KMT2A-rearranged ALL cells seem to initiate a reprogramming process that involves the acquirement (or selection) of myeloid-like characteristics, an ability that may be connected to leukemic lineage switches which are not uncommon in KMT2A-rearranged acute leukemias. Hence, our model represents an important tool to study the complex biology of KMT2A-rearranged leukemia, and its existence and availability requires to be shared with the community.
Preclinical • IO biomarker
|
GNAQ (G Protein Subunit Alpha Q) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CDK6 (Cyclin-dependent kinase 6) • HOXA9 (Homeobox A9) • MEIS1 (Meis Homeobox 1) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • PROM1 (Prominin 1) • RUNX2 (RUNX Family Transcription Factor 2)
|
MLL rearrangement • MYC expression • MLL translocation • MLL fusion
|
Venclexta (venetoclax) • pinometostat (EPZ-5676)
over1year
Single Cell Analysis Identifies Immune Marker IL4I1 As Critical for Leukemogenesis and Immunity (ASH 2022)
Finally, we tested IL4I1 expression in response to Fedratinib, a JAK2 inhibitor, and showed that IL4I1 expression was decreased in responders (R) vs nonresponders (NR) (Fig. 2F). We conclude that IL4I1 is a rational immune therapeutic target for AML and testing of IL4I1 Inhibitor CB-668 through a collaboration with Calithera is underway.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD34 (CD34 molecule) • IL4 (Interleukin 4) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • ANXA5 (Annexin A5)
|
MLL translocation
|
Inrebic (fedratinib) • CB-668
over1year
Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m) (ASH 2022)
Bayesian monitoring of responses begins after the first 10 enrolled patients are evaluable for efficacy. This study is recruiting in the United States and Japan.
Clinical • P1/2 data
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
DSP-5336
over1year
Menin Inhibitor DS-1594b Drives Differentiation and Induces Synergistic Lethality in Combination with Venetoclax in AML Cells with MLL-Rearranged and NPM1 Mutation (ASH 2022)
Here we show in vitro efficacy of DS-1594b, a selective small molecule menin inhibitor, as single agent or in combination with Venetoclax in MLLr and NPM1 mutated cell lines and primary leukemia samples. Preliminary data demonstrate differentiation effects of DS-1594b as single agent in both cell lines and primary AML leukemia samples. Combination effects show synthetic lethality in almost all cell lines except OCI-AML3.
Combination therapy • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NPM1 (Nucleophosmin 1) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • ANXA5 (Annexin A5)
|
NPM1 mutation • MLL rearrangement • BCL2 expression • MLL translocation • MLL fusion
|
Venclexta (venetoclax) • DS-1594
over1year
Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers (ASH 2022)
Front-line therapy for MM was cyclophosphamide, bortezomib, and dexamethasone (CYBORD) followed by autologous stem cell transplant (autoSCT) for all but one patient who received a tandem transplant. Six patients received prior radiation therapy for MM and all but one received lenalidomide as post autoSCT maintenance...Three (16.7%) patients proceeded to alloSCT in first remission while one received alloSCT after salvage chemotherapy with blinatumomab...The median OS of patients with post MM tALL is longer than that of tALL arising after other cancers. With the evolving changes in MM treatment patterns, further and continued evaluation of a larger cohort is recommended.
Clinical
|
ABL1 (ABL proto-oncogene 1) • KMT2A (Lysine Methyltransferase 2A)
|
MLL rearrangement • MLL rearrangement • MLL translocation
|
lenalidomide • bortezomib • cyclophosphamide • Blincyto (blinatumomab) • dexamethasone
over1year
Rare KMT2A-USP2 Fusion Using RNA Next-Generation Sequencing in a Pediatric Mixed Phenotype Acute Leukemia (AMP 2022)
The KMT2A::USP2 fusion has only been reported in selected cases in the literature, initially in an infant with AML and subsequently in isolated cases of ALL and AML. Since disease prognosis has been reported to be related to the localization of breakpoints, the importance of developing methodologies to detect additional KMT2A fusion partners is highlighted within this case. Intriguingly, the finding of this rare KMT2A fusion across different lineage acute leukemias and our recent report of its presence in MPAL may provide links of a common pathway in myeloid/lymphoid lineage derivation.
Clinical • Next-generation sequencing
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
|
KMT2A rearrangement • MLL rearrangement • MLL translocation • MLL fusion
over1year
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. (PubMed, J Clin Oncol)
Compared with historical data, prognosis of patients with noninfant 11q23/KMT2A-rearranged ALL has improved, but allo-HSCT failed to affect outcome. Targeted therapies are needed to reduce relapse and treatment-related mortality rates.
Retrospective data • Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
KMT2A rearrangement • MLL rearrangement • MLL translocation • Chr t(4;11)(q21;q23) • Chr t(9;11)
over1year
Construction of Nalm6-Cas9 Cell Line for Genome-Wide Translocation Sequencing (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Nalm6-Cas9_1-6 monoclonal cell line stably expressing highly active Cas9 protein was obtained, which provided a basis for exploring the translocation of MLL in therapy-related leukemias based on CRISPR/Cas9 genome-wide high-throughput genome-wide translocation sequencing.
Preclinical • Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL translocation
over1year
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. (PubMed, J Clin Exp Hematop)
After 12 cycles of azacitidine treatment, fluorescence in situ hybridization (FISH) for KMT2A split signal indicated that 94% of his bone marrow (BM) cells were positive...The preconditioning regimen consisted of fludarabine, busulfan, melphalan, and antithymocyte globulin (ATG). The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate...The preconditioning regimen and GVHD prophylaxis were the same as those for the first PBSCT without ATG. The patient's PB revealed complete second donor-type chimerism, and the patient has maintained a CR since the second transplantation.
Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL translocation
|
azacitidine • methotrexate • melphalan • fludarabine IV • busulfan
over1year
P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
DSP-5336
over1year
Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)–Rearrangement or Nucleophosmin 1 (NPM1) Mutation (SOHO 2022)
Bayesian monitoring of responses begins after the fi rst 10 enrolled patients are evaluable for effi cacy. This study is recruiting in the United States and Japan.
Clinical • P1/2 data
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
DSP-5336
2years
THE USE OF LEUKAEMIA Q-FUSION GENE SCREENING ASSAY (Q30) IN THE DIAGNOSTIC EVALUATION OF ACUTE MYELOID LEUKAEMIA (AML) (EHA 2022)
These may have been otherwise undetected, but can subsequently be confirmed by FISH, and importantly allow the generation of molecular measurable residual disease (MRD) assays to assess treatment response. We conclude that Q30 is a rapid, simple and sensitive adjunct to conventional FISH in the diagnosis of AML and, in combination with CMA, may preclude the requirement for conventional and time consuming G-banding analysis.
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • AFDN (Afadin, Adherens Junction Formation Factor)
|
MLL translocation
|
Leukemia Q-Fusion Screening Kit
2years
KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA (EHA 2022)
Conclusion Molecular profiling of KMT2A -rearranged AML in Russian Federation reveals the highest incidence of KMT2A-MLLT3 fusion gene and KMT2A intron 9 involvement. Our data also confirms the relatively quiet landscape of accompanying mutations in KMT2A-rearranged AML with RAS pathway most frequently involved.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • KMT2A (Lysine Methyltransferase 2A) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • AFDN (Afadin, Adherens Junction Formation Factor)
|
KRAS mutation • PTEN mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation • MLL translocation • Chr t(9;11)
2years
Hoxa11-mediated reduction of cell migration contributes to myeloid sarcoma formation induced by cooperation of MLL/AF10 with activating KRAS mutation in a mouse transplantation model: Hoxa11 in myeloid sarcoma formation. (PubMed, Neoplasia)
Although silencing Hoxa11 in leukemia cells did not affect Cxcr4 expression, it resulted in increased transwell migration, motility in confined spaces 3 μm in size, and cell protrusion. Our results revealed that Hoxa10 plays an important role in survival and Hoxa11 contributes to MS formation in MLL-t acute myeloid leukemia with activating KRAS mutation.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • KMT2A (Lysine Methyltransferase 2A) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HOXA11 (Homeobox A11)
|
KRAS mutation • KRAS wild-type • RAS wild-type • MLL translocation • CXCR4 expression • HOXA11 overexpression
over2years
MLL-SEPT5 Fusion Transcript in Myelodysplastic Syndrome Patient With t(11;22)(q23;q11). (PubMed, Front Med (Lausanne))
Although the MLL-SEPT5 fusion transcript was occasionally described in acute myeloid leukemia, it was first identified in MDS. Patients with MLL-SEPT5 fusion gene exhibited a poor prognosis even with an aggressive treatment.
Clinical • Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL rearrangement • MLL translocation
over2years
Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL )-Rearrangement or Nucleophosmin 1 (NPM1 ) Mutation (ASH 2021)
Patients on the strong CYP3A4 inhibitors ketoconazole, itraconazole, or isavuconazole, are excluded unless they can be safely taken off these medications or switched to another antifungal medication at least 7 days prior to start of study treatment. Bayesian monitoring of responses will be started after the first 10 enrolled patients are evaluable for efficacy. Study endpoints are summarized in Table 1.
Clinical • P1/2 data
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
itraconazole • DSP-5336
over2years
Database-Guided Analysis for Immunophenotypic Diagnosis and Follow-Up of Acute Myeloid Leukemia With Recurrent Genetic Abnormalities. (PubMed, Front Oncol)
This method excluded AML associated with the following genetic abnormalities: t(8;21), t(15;17), inv(16), and KMT2A translocation, with 92% sensitivity [95% confidence interval (CI): 78.6%-98.3%] and a 98.5% negative predictive value (95% CI: 90.6%-99.8%). Our data showed that the Compass database-guided analysis could identify phenotypic differences between AML groups, representing a useful tool for the identification of DfN patterns.
Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL translocation • Chr t(15;17)
over2years
Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias (ASH 2021)
Criteria for inclusion were a pathologically confirmed diagnosis of AML, age > 18 years, treatment with either decitabine or azacitidine in combination with venetoclax. In contrast to what has been reported for chemotherapy outcomes and in the ELN classification, the KMT2A-MLLT3 translocation was not associated with improved outcomes when compared to other KMT2A translocations. While this study was limited in being retrospective and having a small and heterogeneous population, our findings suggest that venetoclax and HMA are effective in KMT2A rAML and warrant further investigation.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
|
KRAS mutation • NRAS mutation • KMT2A rearrangement • MLL rearrangement • MLL translocation • MLL fusion
|
Venclexta (venetoclax) • azacitidine • decitabine
over2years
Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. (PubMed, J Med Chem)
Compound 63 selectively inhibited MLL histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. Furthermore, 63 displayed good pharmacokinetic properties and suppressed the growth of MV4-11 xenograft tumors in mice after oral administration, first verifying the in vivo efficacy of targeting the WDR5-MLL1 PPI by small molecules.
Journal
|
WDR5 (WD Repeat Domain 5)
|
MLL rearrangement • MLL translocation • MLL fusion
almost3years
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. (PubMed, J Med Chem)
M-1121 is orally bioavailable and shows potent antitumor activity in vivo with tumor regressions observed at tolerated doses in the MV4;11 subcutaneous and disseminated models of MLL-rearranged leukemia. Together, our findings support development of an orally active covalent menin inhibitor as a new therapy for MLLr leukemia.
Journal
|
HOXA9 (Homeobox A9) • MEIS1 (Meis Homeobox 1)
|
MLL rearrangement • MLL rearrangement • MLL translocation
almost3years
The intrinsically disordered proteins MLLT3 (AF9) and MLLT1 (ENL) - multimodal transcriptional switches with roles in normal hematopoiesis, MLL fusion leukemia, and kidney cancer. (PubMed, J Mol Biol)
MLLT1 undergoes phase separation to enhance recruitment of the super elongation complex (SEC) and drive transcription. Mutations in MLLT1 observed in Wilms tumor patients enhance phase separation and transcription to drive an aberrant gene expression program.
Review • Journal
|
BCOR (BCL6 Corepressor) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • MLLT1 (MLLT1 Super Elongation Complex Subunit)
|
MLL mutation • MLL translocation • MLL fusion
almost3years
HOXA11 plays critical roles in disease progression and response to cytarabine in AML. (PubMed, Oncol Rep)
Furthermore, the results of a meta‑analysis using Heuser's AML dataset supported the finding that chemotherapy responders have higher expression levels of HOXA11. These results indicated that the expression of HOXA11 increased cell apoptosis and predicted an improved response to Ara‑C in AML.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • KMT2A (Lysine Methyltransferase 2A) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • RELA (RELA Proto-Oncogene)
|
MLL translocation
|
cytarabine